Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.2024-11-12

Pacific Biosciences of California (NASDAQ:PACB) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$40.0m (down 28% from 3Q 2023).
  • Net loss: US$60.7m (loss narrowed by 9.2% from 3Q 2023).
  • US$0.22 loss per share (improved from US$0.26 loss in 3Q 2023).
NasdaqGS:PACB Earnings and Revenue Growth November 12th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pacific Biosciences of California EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) exceeded analyst estimates by 7.0%.

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 2.0% from a week ago.

Risk Analysis

It is worth noting though that we have found 3 warning signs for Pacific Biosciences of California (1 is a bit concerning!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment